Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DANTROLENE SODIUM vs CARISOPRODOL COMPOUND
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dantrolene sodium dissociates the excitation-contraction coupling in skeletal muscle by inhibiting calcium release from the sarcoplasmic reticulum via ryanodine receptor blockade.
Carisoprodol is a centrally acting muscle relaxant that acts as a prodrug for meprobamate, a barbiturate-like compound with sedative and anxiolytic properties. Its mechanism is thought to involve GABA-A receptor modulation and depression of polysynaptic reflexes in the spinal cord and reticular formation. Aspirin provides analgesic and anti-inflammatory effects via irreversible inhibition of cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis. Codeine is an opioid agonist at mu-opioid receptors, producing analgesia by mimicking endogenous endorphins.
Malignant hyperthermia (treatment and prophylaxis),Upper motor neuron disorders (e.g., spinal cord injury, stroke, cerebral palsy) - spasticity,Neuroleptic malignant syndrome (off-label)
Relief of discomfort associated with acute, painful musculoskeletal conditions,As an adjunct to rest, physical therapy, and other measures
25 mg orally once daily for 7 days; then 25 mg three times daily for 7 days; then 50 mg three times daily for 7 days; then 100 mg three times daily. Maximum daily dose: 400 mg. For malignant hyperthermia: 1 mg/kg intravenously, may repeat up to cumulative dose of 10 mg/kg.
1-2 tablets (carisoprodol 200 mg/aspirin 325 mg) orally 4 times daily.
Terminal elimination half-life is approximately 8-10 hours in adults; may be prolonged to 12-15 hours in elderly or patients with hepatic impairment. Steady-state achieved in 3-4 days.
Carisoprodol has a terminal elimination half-life of approximately 1.5–2 hours; its active metabolite meprobamate has a half-life of 9–12 hours, which may lead to prolonged effects with chronic use.
Hepatic metabolism via oxidative and reductive pathways; minor renal excretion.
Carisoprodol is metabolized by CYP2C19 to meprobamate (active metabolite). Aspirin is hydrolyzed by esterases in the liver and plasma to salicylic acid, which is further conjugated. Codeine is metabolized by CYP2D6 to morphine (active) and by CYP3A4 to norcodeine.
Primarily hepatic metabolism; approximately 25% excreted in urine as metabolites, 45-50% in feces via bile; less than 1% unchanged in urine.
Carisoprodol is primarily metabolized in the liver, with about 50% excreted renally as unchanged drug and metabolites; the major metabolite meprobamate is also renally excreted. Fecal excretion is negligible (<2%).
Approximately 90-95% bound to plasma proteins, primarily albumin.
Carisoprodol is approximately 60% bound to plasma proteins, mainly albumin.
Apparent Vd is 0.5-1.0 L/kg, indicating distribution into total body water and some tissue binding.
Volume of distribution is approximately 0.6–0.8 L/kg, indicating distribution into total body water.
Oral: 70% (range 20-90% due to first-pass metabolism). Not applicable for IV.
Oral bioavailability is nearly complete (close to 100%) due to rapid and extensive absorption.
No specific adjustment required for chronic use; caution in renal impairment as dantrolene is hepatically metabolized and renally excreted. For malignant hyperthermia, use standard dosing.
Contraindicated in severe renal impairment (Cr Cl <30 m L/min). No specific dose adjustment for mild-moderate impairment; use caution.
Contraindicated in active hepatic disease (Child-Pugh class C). For Child-Pugh class A or B, reduce dose by 50% and monitor liver function; do not exceed 100 mg/day.
Contraindicated in severe hepatic impairment (Child-Pugh class C). For moderate impairment, reduce dose or increase interval; specific guidelines not established.
For spasticity in children ≥5 years: initial 0.5 mg/kg orally once daily for 7 days, then 0.5 mg/kg three times daily for 7 days, then increase by 0.5 mg/kg increments every 7 days up to maximum 3 mg/kg/dose three times daily or 100 mg four times daily, whichever is less. For malignant hyperthermia: 1 mg/kg intravenously, may repeat.
Not recommended for pediatric patients due to aspirin content and risk of Reye syndrome.
Initiate at 25 mg orally once daily, increase slowly with monitoring for hepatic and CNS effects. Higher risk of hepatotoxicity and muscle weakness. For malignant hyperthermia, use standard dosing.
Initiate at lowest effective dose; monitor for CNS depression, falls, and aspirin-related bleeding. Avoid in patients ≥65 years due to risks of dizziness, sedation, and GI bleeding.
Hepatotoxicity: Active liver disease or hepatic impairment (e.g., hepatitis, cirrhosis) is a contraindication. Risk is dose-dependent; discontinue if no benefit within 45 days.
None
Hepatotoxicity: monitor liver function tests (LFTs) at baseline and periodically; discontinue if LFTs elevated or symptoms of hepatitis.,Muscle weakness: may impair ability to walk or perform tasks; caution in patients with compromised pulmonary function.,Carcinogenesis: increased incidence of benign and malignant tumors in animal studies; clinical significance unknown.,Photosensitivity: avoid sun exposure; use sunscreen.
Risk of dependence, abuse, and withdrawal with carisoprodol and codeine,CYP2D6 ultrarapid metabolizers may have morphine toxicity from codeine,Reye's syndrome risk in children with viral illness (aspirin),GI bleeding risk with aspirin,Respiratory depression with codeine,Sedation and impaired motor function,Hepatic impairment,Renal impairment
Active hepatic disease (e.g., hepatitis, cirrhosis),Known hypersensitivity to dantrolene,Symptomatic muscle weakness where spasticity is needed to maintain function
Hypersensitivity to carisoprodol, meprobamate, aspirin, codeine, or any component,Porphyria,Acute intermittent porphyria,Children with viral illness (aspirin) due to Reye's syndrome risk,Breastfeeding (codeine),Severe renal or hepatic impairment,GI bleeding or peptic ulcer disease (aspirin),Concurrent use of MAOIs or within 14 days,Respiratory depression (codeine)
Avoid excessive alcohol consumption due to risk of hepatotoxicity. No specific food restrictions; however, maintain adequate hydration to prevent constipation, a common side effect.
Avoid alcohol and grapefruit juice. Alcohol increases CNS depression and risk of hepatotoxicity. Grapefruit juice may inhibit metabolism, leading to increased levels and toxicity.
Dantrolene sodium is not associated with major congenital malformations; however, data are limited. In animal studies, doses above human therapeutic range caused fetal toxicity (reduced fetal weight, increased resorptions). Use during pregnancy only if clearly needed, weighing benefits against potential risks.
Carisoprodol is a pregnancy category C drug. Data from animal studies are insufficient or show adverse effects, but no adequate human studies exist. There is a potential risk of fetal harm if used during the first trimester due to possible neural tube defects based on limited reports. In the second and third trimesters, maternal use may cause neonatal withdrawal symptoms (e.g., irritability, feeding difficulties) and respiratory depression if used near term. Carisoprodol is not recommended during pregnancy unless benefit outweighs risk.
Limited data; dantrolene is excreted into breast milk in small amounts. Milk-to-plasma ratio is not established. Monitor infant for adverse effects (muscle weakness, sedation). Consider alternative therapy if available.
Carisoprodol is excreted into human breast milk. The milk-to-plasma (M/P) ratio is approximately 2-4 based on small studies. An infant would receive a weight-adjusted dose of about 4-8% of the maternal dose, which may cause sedation, drowsiness, or irritability in the neonate. Breastfeeding is not recommended during carisoprodol use, especially in premature infants or those with hepatic impairment. If used, monitor infant for signs of CNS depression.
No specific dosing adjustments are required during pregnancy; however, pharmacokinetic changes (increased volume of distribution, altered protein binding) may necessitate dose adjustments based on clinical response and tolerability. Use lowest effective dose.
No specific dosing adjustments for carisoprodol are established in pregnancy. However, due to increased plasma volume and altered hepatic metabolism in pregnancy, the drug's half-life may be reduced. Clinical monitoring for efficacy and maternal side effects (e.g., drowsiness, dizziness) is recommended. Use the lowest effective dose for the shortest duration. Consider avoidance of the compound formulation with aspirin or other NSAIDs, which have additional risks.
Dantrolene sodium is a direct-acting skeletal muscle relaxant that inhibits calcium release from the sarcoplasmic reticulum. It is the drug of choice for malignant hyperthermia crisis, requiring rapid IV administration at 2.5 mg/kg. For chronic spasticity, start with 25 mg orally daily, titrate slowly to avoid hepatotoxicity; monitor LFTs at baseline and monthly for 3 months, then periodically. Avoid in patients with active liver disease. Dantrolene may cause muscle weakness, including respiratory muscles; caution in patients with compromised pulmonary function.
Carisoprodol is metabolized to meprobamate, a controlled substance with abuse potential; use cautiously in patients with history of substance abuse. Combination with other CNS depressants (e.g., alcohol, benzodiazepines) increases sedation risk. Limit use to 2-3 weeks due to lack of efficacy beyond that and risk of dependence. Avoid in patients with porphyria because carisoprodol may be porphyrinogenic.
Take dantrolene exactly as prescribed; do not increase dose without consulting your doctor.,Report any signs of liver problems: yellowing of skin/eyes, dark urine, abdominal pain, or unexplained fatigue.,Avoid driving or operating heavy machinery until you know how dantrolene affects you; it may cause dizziness or drowsiness.,Do not abruptly stop taking dantrolene; tapering is needed to prevent rebound spasticity.,Inform all healthcare providers you are taking dantrolene, especially before surgery.,Store at room temperature away from moisture and heat.
This medication may cause drowsiness, dizziness, or blurred vision; avoid driving or operating machinery until you know how it affects you.,Do not consume alcohol or other CNS depressants while taking this drug.,Take only as prescribed; do not increase dose or frequency. This drug has abuse potential.,Inform your doctor if you have a history of drug or alcohol abuse, seizures, or liver/kidney disease.,Do not use for longer than 2-3 weeks unless directed by your doctor.
"Dantrolene, a direct-acting skeletal muscle relaxant, may inhibit the hepatic cytochrome P450 (CYP) enzymes responsible for metabolizing the antihistamine clemastine. This metabolic inhibition can lead to elevated plasma concentrations of clemastine, prolonging its sedative and anticholinergic effects. Clinically, patients may experience increased sedation, dizziness, and anticholinergic adverse effects such as dry mouth, blurred vision, and urinary retention."
"The concomitant use of Thiamylal, a barbiturate anesthetic that enhances GABA-A receptor activity, and Dantrolene, a direct-acting skeletal muscle relaxant that inhibits calcium release from the sarcoplasmic reticulum, can lead to additive central nervous system depression and muscle weakness. This interaction may result in prolonged sedation, respiratory depression, and decreased muscle tone, increasing the risk of aspiration and hypoventilation during anesthesia. Clinically, patients may exhibit excessive somnolence delayed recovery from anesthesia, and potential cardiovascular instability."
"Vecuronium, a non-depolarizing neuromuscular blocking agent, enhances the neuromuscular blocking effects of dantrolene, a direct-acting skeletal muscle relaxant used in malignant hyperthermia. This synergistic interaction leads to prolonged and intensified muscle paralysis, increasing the risk of postoperative respiratory depression and prolonged mechanical ventilation. Clinically, patients may exhibit delayed recovery of neuromuscular function and require extended monitoring in the intensive care setting."
"The co-administration of pentobarbital, a barbiturate and potent CYP3A4 inducer, with carisoprodol, a prodrug that is metabolized to its active form, meprobamate, via CYP2C19, may lead to reduced plasma concentrations of meprobamate due to pentobarbital-induced upregulation of CYP2C19, potentially diminishing the sedative and muscle relaxant effects of carisoprodol. However, pentobarbital also acts as a central nervous system (CNS) depressant, and additive CNS depression can occur, increasing the risk of excessive sedation, respiratory depression, and impairment of psychomotor function. Clinical outcomes may include altered therapeutic efficacy of carisoprodol and heightened risk of CNS and respiratory adverse effects."
"Carisoprodol, a centrally acting skeletal muscle relaxant, is metabolized primarily by CYP2C19 to its active metabolite meprobamate. Isoniazid, a first-line antitubercular agent, is a known inhibitor of CYP2C19. When coadministered, isoniazid can decrease the metabolism of carisoprodol, leading to increased plasma concentrations of both carisoprodol and meprobamate. This elevation raises the risk of dose-related adverse effects such as sedation, dizziness, and respiratory depression, and may prolong the duration of muscle relaxant action."
"The combination of sulpiride, an atypical antipsychotic with dopamine D2 receptor antagonism and mild serotonin 5-HT4 agonist properties, and carisoprodol, a centrally acting muscle relaxant metabolized to meprobamate (a barbiturate-like sedative-hypnotic), can result in additive central nervous system (CNS) depression, including sedation, dizziness, and psychomotor impairment. Additionally, both drugs may lower the seizure threshold, increasing the risk of seizures. Sulpiride can also prolong the QT interval, and carisoprodol's sedative effects may mask or exacerbate this cardiotoxicity, potentially leading to ventricular arrhythmias such as torsade de pointes."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DANTROLENE SODIUM vs CARISOPRODOL COMPOUND, answered by our medical review team.
DANTROLENE SODIUM is a Skeletal Muscle Relaxant that works by Dantrolene sodium dissociates the excitation-contraction coupling in skeletal muscle by inhibiting calcium release from the sarcoplasmic reticulum via ryanodine receptor blockade.. CARISOPRODOL COMPOUND is a Skeletal Muscle Relaxant that works by Carisoprodol is a centrally acting muscle relaxant that acts as a prodrug for meprobamate, a barbiturate-like compound with sedative and anxiolytic properties. Its mechanism is thought to involve GABA-A receptor modulation and depression of polysynaptic reflexes in the spinal cord and reticular formation. Aspirin provides analgesic and anti-inflammatory effects via irreversible inhibition of cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis. Codeine is an opioid agonist at mu-opioid receptors, producing analgesia by mimicking endogenous endorphins.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DANTROLENE SODIUM and CARISOPRODOL COMPOUND depend on the specific clinical indication. These are both Skeletal Muscle Relaxant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DANTROLENE SODIUM is: 25 mg orally once daily for 7 days; then 25 mg three times daily for 7 days; then 50 mg three times daily for 7 days; then 100 mg three times daily. Maximum daily dose: 400 mg. For malignant hyperthermia: 1 mg/kg intravenously, may repeat up to cumulative dose of 10 mg/kg.. The standard adult dose of CARISOPRODOL COMPOUND is: 1-2 tablets (carisoprodol 200 mg/aspirin 325 mg) orally 4 times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining DANTROLENE SODIUM and CARISOPRODOL COMPOUND. The risk or severity of adverse effects can be increased when Carisoprodol is combined with Dantrolene. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. DANTROLENE SODIUM is classified as Category A/B. Dantrolene sodium is not associated with major congenital malformations; however, data are limited. In animal studies, doses above human therapeutic range caused fetal toxicity (re. CARISOPRODOL COMPOUND is classified as Category A/B. Carisoprodol is a pregnancy category C drug. Data from animal studies are insufficient or show adverse effects, but no adequate human studies exist. There is a potential risk of fe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.